Author

N. Parajuli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:protein folding & dynamics· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1

Frequent Co-Authors

J. Liu· 2 shared P. Wu· 2 shared X. Wang· 2 shared B. Adhikari· 1 shared B. Aryal· 1 shared B. Pan· 1 shared B. R. Bhattarai· 1 shared D. K. Poudel· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

J. Liu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ser14-RPN6 Phosphorylation Mediates the Activation of 26S Proteasomes by cAMP and Protects against Cardiac Proteotoxic Stress in Mice

L. Yang, N. Parajuli, P. Wu, J. Liu, X. Wang

bioRxiv · Apr 5, 2023Cell Biology

The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction

B. Pan, N. Parajuli, Z. Tian, J. Li, P. Wu, M. T. Lewno, L. Bedford, R. J. Mayer, J. Fang, J. Liu, T. Cui, H. Su, X. Wang

This study identifies the Mocln1-calcineurin-TFEB-p62 pathway as mediating cardiac macroautophagy activation due to proteasomal malfunction.

Circulation Research · Jul 31, 2020Peer-reviewedCell Biology

In Silico Analysis of Secondary Metabolites that Modulates Enzymes of Cholesterol Target

R. Marahatha, S. Basnet, B. R. Bhattarai, P. Budhathoki, B. Aryal, B. Adhikari, G. Lamichhane, D. K. Poudel, N. Parajuli

This paper identifies sixteen secondary metabolites with inhibitory activity against XO and HMGR through in-silico analysis, showing potential as drug candidates for hypercholesterolemia treatment.

bioRxiv · Jul 24, 2020 · PreprintBiochemistry